Dyne Therapeutics, Inc. (DYN) stock
DYNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$17.01−0.98 (-5.45%)
Close on Nov 12, 2026Market cap $3.18BP/E –Yield –
Dyne Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Dyne Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $510.23M, up 32.6% year over year. For fiscal 2025 it was $398.33M, up 41.6% from the year before. The highest annual figure on record is $398.33M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $398.33M | +41.6% |
| FY2024 | Dec 31, 2024 | $281.41M | +33.5% |
| FY2023 | Dec 31, 2023 | $210.76M | +47.6% |
| FY2022 | Dec 31, 2022 | $142.76M | +17.7% |
| FY2021 | Dec 31, 2021 | $121.31M | +168.4% |
| FY2020 | Dec 31, 2020 | $45.20M | +309.4% |
| FY2019 | Dec 31, 2019 | $11.04M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $161.74M | +66.4% |
| Q2 FY2026 | Jun 30, 2026 | $152.17M | +53.3% |
| Q1 FY2026 | Mar 31, 2026 | $100.89M | -5.2% |
| Q4 FY2025 | Dec 31, 2025 | $95.43M | +16.7% |
| Q3 FY2025 | Sep 30, 2025 | $97.22M | +4.8% |
| Q2 FY2025 | Jun 30, 2025 | $99.24M | +59.4% |
| Q1 FY2025 | Mar 31, 2025 | $106.45M | +139.0% |
| Q4 FY2024 | Dec 31, 2024 | $81.81M | +39.0% |
| Q3 FY2024 | Sep 30, 2024 | $92.80M | +68.0% |
| Q2 FY2024 | Jun 30, 2024 | $62.26M | +5.3% |
| Q1 FY2024 | Mar 31, 2024 | $44.54M | +18.7% |
| Q4 FY2023 | Dec 31, 2023 | $58.84M | +77.3% |
| Q3 FY2023 | Sep 30, 2023 | $55.25M | +59.4% |
| Q2 FY2023 | Jun 30, 2023 | $59.13M | +26.7% |
| Q1 FY2023 | Mar 31, 2023 | $37.54M | +32.9% |
| Q4 FY2022 | Dec 31, 2022 | $33.19M | -21.5% |
| Q3 FY2022 | Sep 30, 2022 | $34.67M | -5.0% |
| Q2 FY2022 | Jun 30, 2022 | $46.66M | +95.5% |
| Q1 FY2022 | Mar 31, 2022 | $28.24M | +51.6% |
| Q4 FY2021 | Dec 31, 2021 | $42.30M | +91.4% |
| Q3 FY2021 | Sep 30, 2021 | $36.51M | +277.2% |
| Q2 FY2021 | Jun 30, 2021 | $23.87M | +225.5% |
| Q1 FY2021 | Mar 31, 2021 | $18.63M | +205.9% |
| Q4 FY2020 | Dec 31, 2020 | $22.10M | +418.9% |
| Q3 FY2020 | Sep 30, 2020 | $9.68M | +224.6% |
| Q2 FY2020 | Jun 30, 2020 | $7.33M | – |
| Q1 FY2020 | Mar 31, 2020 | $6.09M | – |
| Q4 FY2019 | Dec 31, 2019 | $4.26M | – |
| Q3 FY2019 | Sep 30, 2019 | $2.98M | – |
See a number that looks wrong?